Healthcare [ 7/13 ] | Medical Distribution [ 154/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 27, 24 | -0.15 Decreased by -7.14% | -0.05 Decreased by -200% |
| Nov 9, 23 | -0.11 Decreased by -27.6 K% | -0.11 |
| Aug 24, 23 | -0.13 Decreased by -316.67% | -0.05 Decreased by -160% |
| May 17, 23 | -0.2 Decreased by -2.1 K% | -0.03 Decreased by -566.67% |
| Mar 30, 23 | -0.14 Decreased by -450% | -0.01 Decreased by -1.3 K% |
| Nov 16, 22 | 0 Increased by +101.33% | -0.05 Increased by +100.8% |
| Aug 24, 22 | 0.06 Increased by +700% | -0.03 Increased by +300% |
| May 17, 22 | 0.01 Decreased by -66.67% | -0.03 Increased by +133.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 11.74 M Decreased by -4.13% | -3.95 M Decreased by -30.45 K% | Decreased by -33.62% Decreased by -31.76 K% |
| Jun 30, 23 | 14.28 M Increased by +0.91% | -4.7 M Decreased by -357.14% | Decreased by -32.9% Decreased by -354.82% |
| Mar 31, 23 | 15.72 M Increased by +12.5% | -5.13 M Decreased by -475.9% | Decreased by -32.64% Decreased by -434.14% |
| Dec 31, 22 | 14.79 M Increased by +13.83% | -7.49 M Decreased by -2.2 K% | Decreased by -50.63% Decreased by -1.94 K% |
| Sep 30, 22 | 12.24 M Increased by +29.69% | 13 K Increased by +101.28% | Increased by +0.11% Increased by +100.99% |
| Jun 30, 22 | 14.15 M Increased by +36.73% | 1.83 M Increased by +530.9% | Increased by +12.91% Increased by +415.15% |
| Mar 31, 22 | 13.97 M Decreased by -9.05% | 1.36 M Increased by +75% | Increased by +9.77% Increased by +92.42% |
| Dec 31, 21 | 13 M Decreased by -15.39% | 357 K Decreased by -54.23% | Increased by +2.75% Decreased by -45.9% |
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.